Skip to content

Dr. Raheel Iftikhar weighs in on AI in blood cancers
Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL
Dr. Feng-Ming Tien on immune landscapes and the future of AML risk stratification
Don’t miss SOHO 2026 poster walks
Japan’s PMDA clears phase 3 trial of eque-cel in relapsed or refractory MM

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Novel therapy INCA in ET shows positive results in early-phase data

Cellular Therapy

Novel therapy INCA in ET shows positive results in early-phase data

Leukemia

Novel therapy INCA in ET shows positive results in early-phase data

Lymphoma

Novel therapy INCA in ET shows positive results in early-phase data

Multiple Myeloma

Novel therapy INCA in ET shows positive results in early-phase data

Myelodysplastic Syndromes

Novel therapy INCA in ET shows positive results in early-phase data

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

April 10, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Myeloproliferative Neoplasms

MPN News

EHA 2025 Myeloproliferative Neoplasms Video Interviews

Novel therapy INCA in ET shows positive results in early-phase data

by Leah Sherwood
July 18, 2025
0 Comments

EHA 2025

EHA 2025 Meetings / Conferences Myeloproliferative Neoplasms

Dr. Kuykendall from EHA 2025: ‘the research is as hot as the conference center’

by SOHO Insider Editors
June 13, 2025
0 Comments

SOHO Insider podcast

Myeloproliferative Neoplasms SOHO Insider Podcast

Drs. Kuykendall and Hobbs on MPN care in 2025

by Leah Sherwood
June 2, 2025
0 Comments

Rio de Janeiro, Brazil - September 10, 2020: ANVISA, National Health Surveillance Agency, on smartphone screen. In Brazil, it exercises sanitary control over all products and services

Myeloproliferative Neoplasms Polycythemia Vera News

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

by SOHO Insider Editors
March 25, 2025
0 Comments

Myeloproliferative Neoplasms

Addition of ropeginterferon alfa-2b to standard PV care is cost effective

by SOHO Insider Editors
February 28, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms News Society Updates

Abstract submissions now open for SOHO 2025

by Leah Sherwood
February 14, 2025
0 Comments

spleen

Myeloproliferative Neoplasms Primary Myelofibrosis

Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?

by SOHO Insider Editors
January 28, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Do driver mutations influence treatment outcomes in myelofibrosis?

by Leah Sherwood
January 10, 2025
0 Comments

Myeloproliferative Neoplasms Polycythemia Vera

Orphan Drug Designation granted to selective JAK2 inhibitor for treatment of polycythemia vera

by SOHO Insider Editors
January 6, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

by sohonews
November 8, 2024
0 Comments

1
2
3

Top Categories

Cellular Therapy

65

Leukemia

101

Lymphoma

111

Multiple Myeloma

87

Myelodysplastic Syndromes

33

Myeloproliferative Neoplasms

21

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Cellular Therapy

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Leukemia

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Lymphoma

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Multiple Myeloma

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Myelodysplastic Syndromes

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Microscope in AI virtual pattern

Dr. Raheel Iftikhar weighs in on AI in blood cancers

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL

Dr. Feng-Ming Tien on immune landscapes and the future of AML risk stratification

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.